# CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation

> **NCT07117305** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhengzhou University** · enrollment: 38 (estimated)

## Conditions studied

- CD7+ Lymphoma
- T Cell Lymphoma

## Interventions

- **DRUG:** CD7 CAR-T combined with autologous hematopoietic stem cell transplantation

## Key facts

- **NCT ID:** NCT07117305
- **Lead sponsor:** Zhengzhou University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-12-01
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2025-08-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07117305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07117305, "CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT07117305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*